Drug Search Results
More Filters [+]

Pipamperone

Alternative Names: pipamperone
Latest Update: 2024-01-31
Latest Update Note: News Article

Product Description

a useful sedative neuroleptic drug in troublesome chronic psychotic patients (Sourced from: https://pubmed.ncbi.nlm.nih.gov/906888/)

Mechanisms of Action: 5-HT2 Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Belgium | Denmark | France | Germany | Greece | Italy | Luxembourg | Netherlands | Switzerland | Tunisia

Approved Indications: None

Known Adverse Events: None

Company: PharmaNeuroBoost
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Pipamperone

Countries in Clinic:

Active Clinical Trial Count: 1

Highest Development Phases

Phase 3: Intellectual Disability

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2016-002859-19

P3

Active, not recruiting

Intellectual Disability

2018-05-22

Recent News Events